The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

Ppp5c  -  protein phosphatase 5, catalytic subunit

Rattus norvegicus

Synonyms: PP5, PPT, Protein phosphatase T, Serine/threonine-protein phosphatase 5
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Ppp5c

  • When expressed in Escherichia coli, the catalytic domain of PPT exhibited protein phosphatase activity (dephosphorylation of phosphorylase a) that was inhibitable by okadaic acid [1].
  • PPT, but not WAY 200070-3, at doses used for protection, elicited lordosis, induced negative feedback inhibition of LH release, and reduced weight gain [2].
  • We explored the dysfunction of tachykinins on monocrotaline (MCT)-induced pulmonary hypertension by using double-stranded preprotachykinin (ds PPT) RNA and neurokinin receptor (NK) antagonists [3].
  • MCT induced right ventricular hypertrophy, as well as increases in pulmonary arterial pressure, PPT mRNA (nodose ganglia and lung tissue), and lung tissue substance P level [3].
  • Total body weight gain was significantly increased in OVX rats compared to SO rats and treatment with E(2) or PPT, but not DPN, significantly decreased total body weight gain to levels that were not significantly different from SO rats [4].

High impact information on Ppp5c

  • Treatment of the transformed PP5 cells with rolipram, an antidepressant in humans and a potent inhibitor of type IV PDEs, reinstated sensitivity to heat shock [5].
  • This domain has previously been found in other proteins involved in the regulation of RNA synthesis or mitosis. mRNA of PPT was predominantly found in brain and, in lower levels, in testis, but was nearly undetectable in spleen, lung, skeletal muscle, kidney, and liver [1].
  • On the other hand, the replacement of 2 Pro for the Ala and Val flanking Thr(32P), to give a new phosphohexapeptide reproducing the phosphorylated site of protein phosphatase inhibitor-1, prevents the protein phosphatase-T activity [6].
  • Moreover, IgG heavy chain 32P labeled in tyrosine is not affected by protein phosphatase-T, while it is dephosphorylated by alkaline phosphatase [6].
  • The NH2-terminal basic residues critical for cAMP-dependent phosphorylation are not required in the dephosphorylation reaction, as both Arg can be removed without impairing the efficiency of protein phosphatase-T toward the phosphothreonyl peptide [6].

Biological context of Ppp5c

  • This study was designed to test whether double-stranded preprotachykinin (ds PPT) RNA, RNA interference (RNAi), prevents the LPS-induced alterations [7].
  • Here, we showed the possibility to attenuate the PPT gene expression by ds RNA, RNA interference (RNAi), in fully developed tissue of rats [3].
  • Using three indicators of neuronal viability and survival, we demonstrated that both the ERalpha selective agonist PPT and the ERbeta selective agonist DPN protected hippocampal neurons against glutamate-induced cell death in a dose-dependent manner, with the maximal response occurring at 100 pM [8].
  • Total food intake was significantly reduced by E(2) and PPT, but not DPN [4].

Anatomical context of Ppp5c

  • This indicates that these cell lines support PPT promoter activity similar to that observed in DRG and determines a novel repressor domain within the promoter [9].
  • This short-term vasorelaxant action of PPT was abolished by the NO synthase inhibitor N(omega)-nitro-l-arginine methyl ester and by endothelium removal [10].
  • One day prior to MCT, bilateral nodose ganglia were microinjected with ds PPT RNA in rats of the RNAi + MCT group or with solvent in the solvent + MCT group [3].
  • Zimelidine treatment of unlesioned animals significantly increased PPT mRNA levels in the neostriatum [11].
  • These results prove that the plasma membrane of a physiologically relevant insulin target tissue contains a PPT phosphatase, distinct from alkaline phosphatase, which catalyzes the dephosphorylation of the insulin receptor beta-subunit [12].

Associations of Ppp5c with chemical compounds

  • The ERalpha-selective agonist propyl pyrazole triol (PPT, 10 mg/kg) and ERbeta-selective agonist WAY 200070-3 (1 mg/kg) produced nearly complete protection of CA1 neurons in approximately 50% of the animals [2].
  • The effect of PPT was restored in preparations from estrogen-replaced OVX rats, whereas DPN remained ineffective even after estrogen replacement [10].
  • PCA-induced 5-HT depletion did not affect stimulant-induced increases in PPT mRNA expression in the striatum [13].
  • In aortic tissues from ovariectomized (OVX) rats, however, neither 17beta-estradiol nor PPT induced acute vascular relaxation [10].
  • Protein concentration, LDH activity, and nitrate/nitrite and IL-6 levels in BALF and nitrate/nitrite and IL-6 levels in the lung increased significantly after trauma-hemorrhage; however, administration of DPN but not PPT significantly improved all parameters [14].

Analytical, diagnostic and therapeutic context of Ppp5c

  • In the present study, the regional distribution of PPT mRNA in the brain of adult rats was characterized by in situ hybridization histochemistry [15].
  • The Mr of protein phosphatase T determined by gel filtration under non-denaturating conditions is about 150 kDa and its activity ratio toward histone H1 phosphorylated by protein kinase C versus histone H1 phosphorylated by cAMP-dependent protein kinase is unusually high [16].


  1. Molecular cloning of a protein serine/threonine phosphatase containing a putative regulatory tetratricopeptide repeat domain. Becker, W., Kentrup, H., Klumpp, S., Schultz, J.E., Joost, H.G. J. Biol. Chem. (1994) [Pubmed]
  2. Estrogen can act via estrogen receptor alpha and beta to protect hippocampal neurons against global ischemia-induced cell death. Miller, N.R., Jover, T., Cohen, H.W., Zukin, R.S., Etgen, A.M. Endocrinology (2005) [Pubmed]
  3. Tachykinin dysfunction attenuates monocrotaline-induced pulmonary hypertension. Chen, M.J., Lai, Y.L. Toxicol. Appl. Pharmacol. (2003) [Pubmed]
  4. Effects of selective estrogen receptor agonists on food intake and body weight gain in rats. Roesch, D.M. Physiol. Behav. (2006) [Pubmed]
  5. Use of a yeast expression system for the isolation and analysis of drug-resistant mutants of a mammalian phosphodiesterase. Pillai, R., Kytle, K., Reyes, A., Colicelli, J. Proc. Natl. Acad. Sci. U.S.A. (1993) [Pubmed]
  6. Dephosphorylation of synthetic phosphopeptides by protein phosphatase-T, a phosphothreonyl protein phosphatase. Deana, A.D., Marchiori, F., Meggio, F., Pinna, L.A. J. Biol. Chem. (1982) [Pubmed]
  7. RNA interference prevents lipopolysaccharide-induced preprotachykinin gene expression. Lai, Y.L., Yu, S.C., Chen, M.J. Toxicol. Appl. Pharmacol. (2003) [Pubmed]
  8. Estrogen receptor subtypes alpha and beta contribute to neuroprotection and increased Bcl-2 expression in primary hippocampal neurons. Zhao, L., Wu, T.W., Brinton, R.D. Brain Res. (2004) [Pubmed]
  9. Novel cell lines for the analysis of preprotachykinin A gene expression identify a repressor domain 3' of the major transcriptional start site. Fiskerstrand, C.E., Newey, P., Ebrahimi, B., Gerrard, L., Harrison, P., McGregor, G.P., Quinn, J.P. Biochem. J. (1999) [Pubmed]
  10. The acute estrogenic dilation of rat aorta is mediated solely by selective estrogen receptor-alpha agonists and is abolished by estrogen deprivation. Bolego, C., Cignarella, A., Sanvito, P., Pelosi, V., Pellegatta, F., Puglisi, L., Pinna, C. J. Pharmacol. Exp. Ther. (2005) [Pubmed]
  11. Serotonin regulation of neostriatal tachykinins following neonatal 6-hydroxydopamine lesions. Walker, P.D., Riley, L.A., Hart, R.P., Jonakait, G.M. Brain Res. (1991) [Pubmed]
  12. A protein phosphotyrosine phosphatase distinct from alkaline phosphatase with activity against the insulin receptor. Strout, H.V., Vicario, P.P., Saperstein, R., Slater, E.E. Biochem. Biophys. Res. Commun. (1988) [Pubmed]
  13. Blockade of stimulant-induced preprodynorphin mRNA expression in the striatal matrix by serotonin depletion. Horner, K.A., Adams, D.H., Hanson, G.R., Keefe, K.A. Neuroscience (2005) [Pubmed]
  14. Salutary effects of estrogen receptor-beta agonist on lung injury after trauma-hemorrhage. Yu, H.P., Hsieh, Y.C., Suzuki, T., Shimizu, T., Choudhry, M.A., Schwacha, M.G., Chaudry, I.H. Am. J. Physiol. Lung Cell Mol. Physiol. (2006) [Pubmed]
  15. Distribution of the mRNA for protein phosphatase T in rat brain. Becker, W., Buttini, M., Limonta, S., Boddeke, H., Joost, H.G. Brain Res. Mol. Brain Res. (1996) [Pubmed]
  16. Identification of pseudo 'phosphothreonyl-specific' protein phosphatase T with a fraction of polycation-stimulated protein phosphatase 2A. Deana, A.D., Pinna, L.A. Biochim. Biophys. Acta (1988) [Pubmed]
WikiGenes - Universities